Clinical Trial Update: Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04) [Phase 3]

View source ↗

Summary

A Phase III randomized trial evaluating neoadjuvant chemotherapy in combination with toripalimab for hormone receptor-positive, HER2-negative breast cancer; rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: HR+/HER2- Breast Cancer | Phase 3 | Status: RECRUITING